Los puntos clave no están disponibles para este artículo en este momento.
A triplet regimen is usually needed at relapse, with the choice of regimen varying with each successive relapse. Chimeric antigen receptor T (CAR-T) cell therapy and bispecific antibodies are additional options.
S. Vincent Rajkumar (Fri,) studied this question.